Nanomedicines for kidney diseases Academic Article uri icon

Overview

MeSH Major

  • Amides
  • Amlodipine
  • Blood Pressure
  • Fumarates
  • Hydrochlorothiazide
  • Hypertension
  • Minority Groups

abstract

  • Nanomedicines have been the subject of great interest for the treatment, diagnosis, and research of disease; however, few specifically address kidney disorders. Nanotechnology can confer significant benefits to medicine, such as the targeted delivery of drugs to specific tissues. Nanomedicines in the clinic have increased drug solubility, reduced off-target side effects, and provided novel diagnostic tools. There is an increasing cohort of nanomaterials that may have implications for kidney disease. Here, we review nanomaterial properties that are potentially applicable to kidney research and therapy, and we highlight clinical areas of need that may benefit from kidney nanomedicines.

publication date

  • October 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5064150

Digital Object Identifier (DOI)

  • 10.1016/j.kint.2016.03.041

PubMed ID

  • 27292222

Additional Document Info

start page

  • 740

end page

  • 5

volume

  • 90

number

  • 4